3,491 results on '"Merseburger, A."'
Search Results
2. Risikoadaptierte Prostatakarzinomfrüherkennung 2.0 – Positionspapier der Deutschen Gesellschaft für Urologie 2024
3. Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type 2 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study
4. Proteomic analysis of the urothelial cancer landscape
5. Endoscopic intervention versus radical nephroureterectomy for the management of localized upper urinary tract urothelial carcinoma: a systematic review and meta-analysis of comparative studies
6. Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network
7. Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells
8. The landscape of penile cancer research in Germany and Austria: a survey among professors in academic centers holding chair positions and results of a literature search
9. Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial
10. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
11. Notfälle (Krankheiten, Verletzungen)
12. Epidemiologie des metastasierten Prostatakarzinoms
13. Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study
14. Retrospektive NIS-Studie zur HER2-Expression beim Urothelkarzinom
15. Perception of cure in prostate cancer: human-led and artificial intelligence-assisted landscape review and linguistic analysis of literature, social media and policy documents
16. Benchmark of tools for in silico prediction of MHC class I and class II genotypes from NGS data
17. Medikamentöse Therapie des metastasierten Nierenzellkarzinoms
18. Impact of Peritoneal Interposition Flap on Patients Undergoing Robot-assisted Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review and Meta-analysis of Randomized Controlled Trials
19. Salvage high-dose-rate interventional radiotherapy (brachytherapy) for locally relapsed prostate cancer after radical prostatectomy and subsequent external irradiation
20. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations
21. Radiomics vs radiologist in prostate cancer. Results from a systematic review
22. Das metastasierte kastrationsresistente Prostatakarzinom: praxisrelevante Hilfestellungen für individuelle Therapieentscheidungen
23. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study
24. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty
25. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
26. The alternative renin-angiotensin-system (RAS) signalling pathway in prostate cancer and its link to the current COVID-19 pandemic
27. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
28. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
29. Global distribution of nonexchangeable stable hydrogen isotope ratios of topsoil clay fractions
30. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
31. Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients
32. Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer
33. Medikamentöse Therapie des metastasierten Nierenzellkarzinoms
34. Systemtherapie des mCRPC
35. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
36. The dilemma of 12/14F ureteral access sheath (UAS) usage: a case control study
37. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis
38. Therapiesequenzen und -dauer beim mCRPC: Eine retrospektive Aufarbeitung der Lübecker mCRPC-Kohorte.
39. Enfortumab vedotin as a salvage option as 5th line therapy for metastatic urothelial bladder cancer.
40. Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy.
41. Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate Cancer
42. Comprehensive Nomogram for Prediction of the Uric Acid Composition of Ureteral Stones as a Part of Tailored Stone Therapy
43. A Global Trend Analysis of Kidney Cancer Incidence and Mortality and Their Associations with Smoking, Alcohol Consumption, and Metabolic Syndrome
44. Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes
45. Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma
46. Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitals
47. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
48. CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasia
49. Incorporation of hydrogen from ambient water into the C-bonded H pool during litter decomposition
50. Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.